The Healthcare Stage I Episode 11 I MDI's Novel Solution for Optimizing Health Outcomes & Reducing Costs in Polypharmacy Patients

In this episode, we sit down with Avishai Ben Tovim, CEO of MDI, a company founded in 2019. MDI has developed a groundbreaking risk analysis system for polypharmacy patients, designed to manage complex cases and provide accurate clinical recommendations for treatment optimization and risk mitigation.

Despite increasing efforts to prevent adverse drug reactions over the past decade, drug-induced hospitalizations and mortality rates continue to rise. MDI's medication management platform addresses this issue by scaling up the prevention process, helping physicians and payors avoid the clinical and financial consequences of drug-related adverse events.

The platform conducts comprehensive drug-related risk analyses for entire populations, identifying at-risk individuals and providing financial projections even before conducting per-patient analyses. By analyzing thousands of pharmacological and medical parameters, MDI's algorithms enable payors and physicians to pinpoint precise and immediate health risks, generating evidence-based clinical recommendations to reduce these risks.

MDI's mission is to enable Value Based Care, focusing on clinical quality and cost reduction. Join us as we discuss MDI's innovative solution, the validation they generated, , and their future goals.

🎧 This Podcast is also available in a video format on “The Healthcare Stage” YouTube channel